Skip to main content
. 2022 Jul 4;9:874445. doi: 10.3389/fmed.2022.874445

Table 1.

Demographics and clinical variables of patients with SJS/TEN from 2008 to 2021.

Variable % (mean or count) n = 77
Age (years old) 6–93 (45)
Menstrual status
Premenstrual 4% (3)
Menstruating 45% (35)
post-menstrual/hysterectomy 43% (33)
Sexual activity
Yes 17% (13)
No 22% (17)
Not specified 63% (48)
Diagnosis
SJS 55% (42)
TEN 43% (33)
Extent of vulvovaginal involvement
Vulvar involvement 55% (42)
Vaginal involvement 39% (30)
Gynecology consult 43% (33)
Vaginal treatment recommendations (a) 70% (21)
Dilator recommended 70% (21)
Dilator used 67% (20)
Steroid cream/ointment 71% (30)
No vulvar treatment recommendations + 19% (8)
Vulvar treatment recommendations (b) 81% (34)
Gauze only 19% (5)
Topical Steroid 45% (19)
Other 36% (15)
Menstrual suppression (c) 49% (17)
Antifungal 17% (13)

(a) recommendation for vaginal dilator of the patients with documented vaginal involvement (n = 30). (b) Vulvar treatment recommendations of the patients with vulvar involvement (n = 42). (c) menstrual suppression of menstruating patients (n = 35).

HHS Vulnerability Disclosure